{"ticker": {"uuid": "302b7172-70b5-487e-bcf7-5154478835d9", "symbol": "PHAR", "name": "Pharming Group NV", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pharming Group to report Q2 and H1 2026 results on July 30", "summary": "Pharming Group N.V. will release its Q2 and H1 2026 preliminary financial results on July 30, 2026, including a business update. A conference call and webcast for analysts and investors are scheduled for the same day at 13:30 CEST. Participants must register in advance to join th", "url": "https://scanx.trade/stock-market-news/companies/pharming-group-to-report-q2-and-h1-2026-results-on-july-30/45727708", "source_name": "scanx.trade", "published_at": "2026-07-16T06:41:01", "published_display": "16 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30", "summary": "Pharming Group N.V. announced that it will report its unaudited financial results for the second quarter and first half of 2026 on Thursday, July 30, 2026. The company will also provide a business update and host a conference call and webcast for analysts and investors on the sam", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328224/0/en/pharming-group-to-report-second-quarter-and-first-half-2026-financial-results-and-provide-business-update-on-july-30.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T05:41:56", "published_display": "16 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group (PHARM) M&A Announcement Summary", "summary": "Pharming Group announced the acquisition of Abliva AB for approximately $66.1 million through a public tender offer. This strategic move aims to expand Pharming's rare disease pipeline with Abliva's lead asset, KL1333, a first-in-class therapy for primary mitochondrial disease wi", "url": "https://quartr.com/events/pharming-group-n-v-pharm-m-a-announcement_FkNLYUc1", "source_name": "Quartr", "published_at": "2026-07-15T22:41:56", "published_display": "15 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XS276301888 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the XS276301888 bond issued by Pharming Group N.V. Key metrics such as the 4.50% coupon, April 25, 2029, maturity date, and an outstanding amount of EUR 100 million are highlighted. The bond's face value and minimum denomination are bot", "url": "https://www.tradingview.com/symbols/FWB-XS276301888/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-15T19:41:01", "published_display": "15 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XS276301888 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides the coupon profile for the Pharming Group N.V. bond XS276301888, highlighting its current coupon rate of 4.50%. It indicates that the next interest payment is scheduled for October 26, 2026. The page offers an overview of the bond's interest payment details,", "url": "https://www.tradingview.com/symbols/FWB-XS276301888/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T06:40:04", "published_display": "15 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pharming announces US FDA approval of Joenja\u00ae (leniolisib) as the first and only treatment indicated for APDS", "summary": "Pharming Group N.V. has received US FDA approval for Joenja\u00ae (leniolisib), making it the first and only approved treatment for activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS) in adult and pediatric patients aged 12 and older. Joenja\u00ae, an oral PI3K\u03b4 inhibitor, is", "url": "https://www.prnewswire.co.uk/news-releases/regulatory-news/pharming-announces-us-fda-approval-of-joenja-leniolisib-as-the-first-and-only-treatment-indicated-for-apds-301781147.html", "source_name": "PR Newswire UK", "published_at": "2026-07-12T21:39:37", "published_display": "12 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Pharming Group N.V. (PHAR)", "summary": "This article analyzes the historical performance of an investment in Pharming Group N.V. (PHAR), a global biopharmaceutical company focusing on rare diseases. It details how a $1,000 investment would have performed over one and five years, indicating positive returns but no 10-ye", "url": "https://www.stocktitan.net/tools/stock-return-calculator/PHAR", "source_name": "Stock Titan", "published_at": "2026-07-12T02:11:47", "published_display": "12 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (PHAR) and Scalable Risk", "summary": "This article analyzes Pharming Group N.v. (NASDAQ: PHAR), highlighting a near-term neutral sentiment amidst mid and long-term strength. It identifies a significant 69.0:1 risk-reward setup targeting a 21.3% gain with minimal risk, and outlines institutional trading strategies, in", "url": "https://news.stocktradersdaily.com/news_release/91/Understanding_the_Setup:_PHAR_and_Scalable_Risk_071126081401_1783815241.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T20:11:47", "published_display": "11 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group (PHARM) Q1 2025 earnings summary", "summary": "Pharming Group reported strong Q1 2025 revenues of $79.1 million, a 42% year-over-year increase, driven by significant growth in RUCONEST\u00ae and Joenja\u00ae sales. The company completed the acquisition of Abliva, expanding its pipeline, and raised its 2025 revenue guidance to $325\u2013340 ", "url": "https://quartr.com/events/pharming-group-n-v-pharm-q1-2025_FkNLYx79", "source_name": "Quartr", "published_at": "2026-07-08T08:09:31", "published_display": "08 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pharming Group NV \u2013 EURONEXT:PHARM", "summary": "This article provides the \"Price to book forward\" financial metric for Pharming Group NV (EURONEXT:PHARM). The content displays a table with period, value, change, and change percentage, specifically stating \"No trades\" and \"Market closed.\" It appears to be a financial data snipp", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:10:12", "published_display": "07 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline", "summary": "Pharming Group N.V. reported an 8% revenue decline in Q1 2026, leading to a 22.15% stock price drop, primarily due to competitive pressures on its RUCONEST product. Despite this, the company saw substantial growth in its Joenja franchise and reaffirmed its full-year 2026 revenue ", "url": "https://www.investing.com/news/company-news/pharming-q1-2026-slides-joenja-growth-offset-by-ruconest-decline-93CH-4668282", "source_name": "Investing.com", "published_at": "2026-07-06T06:40:19", "published_display": "06 Jul 2026 06:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "High Growth Tech Stocks In Europe Featuring 3 Promising Picks", "summary": "This article identifies three promising high-growth tech stocks in Europe: Pharming Group, Acast, and Dustin Group. It highlights their recent developments, financial performance, and growth prospects within the context of a resilient European market. The piece offers a brief ove", "url": "https://simplywall.st/stocks/nl/pharmaceuticals-biotech/ams-pharm/pharming-group-shares/news/high-growth-tech-stocks-in-europe-featuring-3-promising-pick/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T05:43:27", "published_display": "06 Jul 2026 05:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group N.V. Stock 12\u2011Month Price Target Raised to $32.69, Implies 137% Upside", "summary": "Analysts have raised the 12-monthprice target for Pharming Group N.V. (PHARM) stock to $32.69 from $31.09, based on estimates from 5 analysts. This new target implies a potential upside of approximately 137% from the July 2nd closing price. The consensus rating for the stock rema", "url": "https://www.tradingview.com/news/tradingview:cbc0a191bcaab:0-pharming-group-n-v-stock-12-month-price-target-raised-to-32-69-implies-137-upside/", "source_name": "TradingView", "published_at": "2026-07-04T22:10:14", "published_display": "04 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV - Depositary receipt (PHAR) price target increased by 43.79% to 25.84", "summary": "This article reports that the price target for Pharming Group NV (PHAR) depositary receipts has been increased by 43.79% to 25.84. No further details are provided in the snippet.", "url": "https://www.msn.com/en-us/money/topstocks/pharming-group-nv-depositary-receipt-phar-price-target-increased-by-43-79-to-25-84/ar-AA20ZBmJ", "source_name": "MSN", "published_at": "2026-07-04T18:43:27", "published_display": "04 Jul 2026 18:43", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pharming Group NV \u2013 EURONEXT:PHARM", "summary": "The article provides financial data on Pharming Group NV (EURONEXT:PHARM), specifically highlighting its enterprise value to EBIT forward. It appears to be a financial data snippet from TradingView, offering an overview of the company's financial metrics. The content is concise a", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:40:49", "published_display": "01 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pharming Group NV \u2013 EURONEXT:PHARM", "summary": "This article provides a brief overview of Pharming Group NV (EURONEXT:PHARM) on TradingView, focusing on its financial metrics, specifically the price to sales forward. It does not offer any specific financial figures or analysis but highlights the company's presence on the platf", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:39:22", "published_display": "01 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (PHAR) That Institutions Follow", "summary": "This article analyzes Pharming Group N.v. (NASDAQ: PHAR) based on AI-generated technical signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup targeting a 21.2% gain, and outlines three distinct trading strategies (Position, Momentum Breako", "url": "https://news.stocktradersdaily.com/news_release/101/The_Technical_Signals_Behind_PHAR_That_Institutions_Follow_063026070602_1782860762.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T19:06:00", "published_display": "30 Jun 2026 19:06", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V. (PHAR) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pharming Group N.V. (NASDAQ: PHAR) securities. This investigation follows a significant stock price drop after the FDA issued a Complete Response Letter to Pharming's sNDA for Joenja\u00ae,", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-pharming-group-nv-phar", "source_name": "The National Law Review", "published_at": "2026-06-30T12:39:22", "published_display": "30 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2QLQY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and forecast for Pharming Group NV Sponsored ADR (A2QLQY) for 2027, based on analysis from 6 analysts. It states a price target of 26.85 and includes sections for annual and quarterly EPS and revenue metrics. The content also contains a discla", "url": "https://www.tradingview.com/symbols/LS-A2QLQY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T11:41:52", "published_display": "29 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR)", "summary": "This article provides access to the financial actuals and estimates for Pharming Group N.V. (NASDAQ: PHAR) on TradingView. It allows users to explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends over time ac", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:36", "published_display": "27 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the 1-year price target forecast for Pharming Group NV Sponsored ADR (PHG) based on input from 6 analysts. It states a price target of 26.85 but notes that maximum and minimum estimates were not provided. The article also touches on analyst ratings, EPS, and", "url": "https://www.tradingview.com/symbols/MUN-PHG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:36", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case", "summary": "Pharming Group's fair value estimate has been raised from \u20ac2.11 to \u20ac2.36 by analysts, driven by adjusted revenue growth assumptions and revised future P/E multiples. This update reflects a balance of optimism regarding the company's growth potential, particularly with its Joenja ", "url": "https://finance.yahoo.com/markets/stocks/articles/pharming-group-enxtam-pharm-stock-130805614.html", "source_name": "Market source", "published_at": "2026-06-27T09:08:00", "published_display": "27 Jun 2026 09:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV Actuals & Estimates (EURONEXT:PHARM)", "summary": "This article provides an overview of Pharming Group NV (EURONEXT:PHARM) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers various metrics such as market capitalization, volatility, earnings, revenue, and EBITDA, while als", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:52", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV Actuals & Estimates (AQUISUK:PHARMA)", "summary": "This article provides details on Pharming Group NV (PHARMA) stock, including financial actuals and estimates. It covers analyst price targets with a range of 1.80 EUR to 3.45 EUR, historical price data, upcoming earnings dates, and past financial performance such as revenue, net ", "url": "https://www.tradingview.com/symbols/AQUISUK-PHARMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:31", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV (PHAR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pharming Group NV (PHAR), focusing on indicators and moving averages to assess its stock performance. It details various technical indicators like MACD, RSI, and STOCH, along with an analysis of moving averages (MA5 to MA200), conclud", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phar/technical", "source_name": "TradingKey", "published_at": "2026-06-23T01:40:06", "published_display": "23 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Pharming Group N.v. (PHAR) Risk Zones", "summary": "The article provides a detailed analysis of Pharming Group N.v. (PHAR) stock, highlighting positive near-term sentiment within a long-term strength context despite elevated downside risk due to a lack of additional long-term support signals. It outlines three AI-generated institu", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Pharming_Group_N.v._PHAR_Risk_Zones_061926055401_1781906041.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T01:10:13", "published_display": "20 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV (PHAR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Pharming Group NV (PHAR), indicating a \"Strong Buy\" analyst rating based on 6 analysts. It highlights that relevant financial forecasting data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. The article al", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phar/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:54", "published_display": "18 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group Says Marketing Application for Immunodeficiency Disorder Drug Accepted by FDA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pharming-group-says-marketing-application-073748059.html", "source_name": "MT Newswires", "published_at": "2026-06-04T07:37:48+00:00", "published_display": "04 Jun 2026 07:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja\u00ae (leniolisib) to treat children aged 4 to 11 years with APDS", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pharming-announces-u-fda-acceptance-050000350.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T05:00:00+00:00", "published_display": "04 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxQRHV2SjcyUngyaHBTRl95M1BYSU80c0J2X09vbEhISWMyNFlvbk9NVV84RkpuNDRiZ1lkRmdJalRqRUJEc1Y2QnFZakZlTGg0dXZzclJ4aE9JOUpEWDJVTWI4WU54X25KWmpGc3dTYkVfc2pFdEY4QXF0Q05QWDBOU2dWSGFSSFpRUHhYTklXWS1TaHFvM1FDQndpanN3aC1QMVUzaG1CVEkzUDFKd0J5d3BLR2UzZWFQczBEMElHdEpXNmZFWlExOV83TWtnMmNQUkRVOEVDbkpMNW1wbjYxMUo3U0Vsb0E4b1BQVEVWeW9wM2otZElRUlkycmcyVjY1YnV5d3hIVkw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group announces results of 2026 Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQc21sTkFCWVFoLXBNbUlDZHVncG9ydFdjNlBpU1RJY0ZJbWowRjQ4M3pwZVljMDg0bUpsejlleFd6VU05ZnpOQnZYeWlrbzFlVFFxcEkxYzJCV0ZldjIxeFlibnl4Y2tjaU5oODlJaG1lLTl6VElnc2s2amVHUWNLVlBtRTIxZXJGRnY2WWZLRmlqOEFCOEZuNm13WUd5ak5lSHk3aEs4cE11QlpEWGpIZnRrUDJObDhrZFVWajgxUVN2elJ2NWdscjJfVlpXNnhFNGhjanRRRHFDXzRrenFXaG0yV0tydw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Says European Commission Grants Marketing Authorization to Joenja", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pharming-says-european-commission-grants-195934063.html", "source_name": "MT Newswires", "published_at": "2026-05-22T19:59:34+00:00", "published_display": "22 May 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Commission grants marketing authorization to Pharming\u2019s Joenja\u00ae (leniolisib) \u2013 the first approved treatment for APDS in the European Union", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/european-commission-grants-marketing-authorization-193000990.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T19:30:00+00:00", "published_display": "22 May 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pharming Group reports first quarter 2026 financial", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxQdk9XUmNoRjVtLXJkR3VWZ0RxMkluaHQxd0JWaXNva2NuOVRIdkxXUGsxdnRlN0VqUXFqRW9NQ2NYVy1GLVZvSGFoTkUwaXlzaXM4R05WUTFpbHlSNjBVQWwzZXVhOXNLQ2lvWm5ZM3MxclBRNm0wWDFlbVlSa3d1RGVKdnhmbFNrOEdOd3B0STgwVUFUNDVKSEg2RlFVMHl2dU9BeHZnaTZUaU83YktyMGwxNkFreGdsbmxpSUFPWlBFdXpuZHNpSHhMOGotOUQzcDBKTzZVa1Nvd21ieEw3OTFxLUE1RjRJc01pYXNFd1B2bTRfTUZRNlpoWGdfdFd0a21WWlJ3Ukk1cEdKSlNyX2U1OHo5R1lpcjJaVFJtTzFidkVtTGFIbzJNdk94WW1zVjY0cy11aVJLWlNuTEg4X0pta1A?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group N.V. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PHAR) 2026-05-07", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOY1gwbEJtUkF1QVZ4RXJRUlpGaS1DdVNzcUthdlNpdVZNZlN0dkk5WGtoRjFNUC1rYmFGUEJuZFVZaXplOHY0SzRNc3lQQWtYWm4wblBMNHJyQzZUdUtHa3p5b1A1b29oWGt4T3doYmlCTE9SZE4xVUdZNzNsWUVQcmRHWFRVaC1RWU1qQjZSLXRRRFR3Ym0tNzgwVU1tUGZVaXVnRw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pharming Group: Crossing From Speculation To Profitability (NASDAQ:PHAR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOb1U3ODFlTU5Mb1Raa2xKZFFnM1huZXhKdUpwYjdKMnpkSTYzZWhEWEk3c1IwTVVHQlQ0THNsZl9JUVFSaFBzcGN6cFVLaF8wYVMwdUZ2SVJrNXFXSUVPRWJWZnZHRDkyYkNKeVBia29HcElSN1YxdTNqSlhHY2hlTjl5VjFINFRTV291LXAtNzFuQ0x1RVpGRkdaN25Yb21QVXY5aDg4Yw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Open Week In The Red As Gold, Silver Extend Sharp Selloff: Why ORCL, PLTR, DIS, PHAR, ELPW Are On Traders' Radar Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNeU00SlZPU3FCOENMUTZwMGJnYkFjTy1jNndGTzFPQ2VmN0JkTUlXcVp1YkVuRHRaNllWQkJDU09LaEpSX0NpV0tFMm1xeXNRTUdVTTJ3RXlRUl9xMDE0V1ZkLWlpNzVOWnZvcGktbjBkeE1qbFVhRE5NUVF1alRtMEZBQWNnbnFEaUFWZXdwOW5HMnJWODJTOUh5bGk0bWFpeUZwNjFhdTVyMTdwU01rVzdhdUg5ME5UalM0RnBsMm8xcGZv?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group stock tumbles after FDA issues Complete Response Letter By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOWEhQQjFSTnpiZ0RsUGJQUEtzM3ExUjBjazgwVmhaUWNXV0VyRzBsQW54LWp3a3kySEdYUVJiRE5ibjdqRFhlLUlELWpRWk02R0VBWHdPOVN6eFQtRm5EeWdITTNJYUpJRzNySEcyMVFDYVNPUjRJU1pXa0N2TlJNQUxXT3czWmlteGxmNUJBVy1GUXZyZEFXOUVyeVFWOG01OU9vNXlkV2NjWU04N24wSjIwdFdsN3hDWlBQYk5qN0M2a1o5SFNoYkJWSQ?oc=5", "source_name": "Investing.com UK", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pharming Group to report Q2 and H1 2026 results on July 30", "summary": "Pharming Group N.V. will release its Q2 and H1 2026 preliminary financial results on July 30, 2026, including a business update. A conference call and webcast for analysts and investors are scheduled for the same day at 13:30 CEST. Participants must register in advance to join th", "url": "https://scanx.trade/stock-market-news/companies/pharming-group-to-report-q2-and-h1-2026-results-on-july-30/45727708", "source_name": "scanx.trade", "published_at": "2026-07-16T06:41:01", "published_display": "16 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30", "summary": "Pharming Group N.V. announced that it will report its unaudited financial results for the second quarter and first half of 2026 on Thursday, July 30, 2026. The company will also provide a business update and host a conference call and webcast for analysts and investors on the sam", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328224/0/en/pharming-group-to-report-second-quarter-and-first-half-2026-financial-results-and-provide-business-update-on-july-30.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T05:41:56", "published_display": "16 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group (PHARM) M&A Announcement Summary", "summary": "Pharming Group announced the acquisition of Abliva AB for approximately $66.1 million through a public tender offer. This strategic move aims to expand Pharming's rare disease pipeline with Abliva's lead asset, KL1333, a first-in-class therapy for primary mitochondrial disease wi", "url": "https://quartr.com/events/pharming-group-n-v-pharm-m-a-announcement_FkNLYUc1", "source_name": "Quartr", "published_at": "2026-07-15T22:41:56", "published_display": "15 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XS276301888 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the XS276301888 bond issued by Pharming Group N.V. Key metrics such as the 4.50% coupon, April 25, 2029, maturity date, and an outstanding amount of EUR 100 million are highlighted. The bond's face value and minimum denomination are bot", "url": "https://www.tradingview.com/symbols/FWB-XS276301888/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-15T19:41:01", "published_display": "15 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XS276301888 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides the coupon profile for the Pharming Group N.V. bond XS276301888, highlighting its current coupon rate of 4.50%. It indicates that the next interest payment is scheduled for October 26, 2026. The page offers an overview of the bond's interest payment details,", "url": "https://www.tradingview.com/symbols/FWB-XS276301888/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T06:40:04", "published_display": "15 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming announces US FDA approval of Joenja\u00ae (leniolisib) as the first and only treatment indicated for APDS", "summary": "Pharming Group N.V. has received US FDA approval for Joenja\u00ae (leniolisib), making it the first and only approved treatment for activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS) in adult and pediatric patients aged 12 and older. Joenja\u00ae, an oral PI3K\u03b4 inhibitor, is", "url": "https://www.prnewswire.co.uk/news-releases/regulatory-news/pharming-announces-us-fda-approval-of-joenja-leniolisib-as-the-first-and-only-treatment-indicated-for-apds-301781147.html", "source_name": "PR Newswire UK", "published_at": "2026-07-12T21:39:37", "published_display": "12 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Pharming Group N.V. (PHAR)", "summary": "This article analyzes the historical performance of an investment in Pharming Group N.V. (PHAR), a global biopharmaceutical company focusing on rare diseases. It details how a $1,000 investment would have performed over one and five years, indicating positive returns but no 10-ye", "url": "https://www.stocktitan.net/tools/stock-return-calculator/PHAR", "source_name": "Stock Titan", "published_at": "2026-07-12T02:11:47", "published_display": "12 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (PHAR) and Scalable Risk", "summary": "This article analyzes Pharming Group N.v. (NASDAQ: PHAR), highlighting a near-term neutral sentiment amidst mid and long-term strength. It identifies a significant 69.0:1 risk-reward setup targeting a 21.3% gain with minimal risk, and outlines institutional trading strategies, in", "url": "https://news.stocktradersdaily.com/news_release/91/Understanding_the_Setup:_PHAR_and_Scalable_Risk_071126081401_1783815241.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T20:11:47", "published_display": "11 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group (PHARM) Q1 2025 earnings summary", "summary": "Pharming Group reported strong Q1 2025 revenues of $79.1 million, a 42% year-over-year increase, driven by significant growth in RUCONEST\u00ae and Joenja\u00ae sales. The company completed the acquisition of Abliva, expanding its pipeline, and raised its 2025 revenue guidance to $325\u2013340 ", "url": "https://quartr.com/events/pharming-group-n-v-pharm-q1-2025_FkNLYx79", "source_name": "Quartr", "published_at": "2026-07-08T08:09:31", "published_display": "08 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pharming Group NV \u2013 EURONEXT:PHARM", "summary": "This article provides the \"Price to book forward\" financial metric for Pharming Group NV (EURONEXT:PHARM). The content displays a table with period, value, change, and change percentage, specifically stating \"No trades\" and \"Market closed.\" It appears to be a financial data snipp", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:10:12", "published_display": "07 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline", "summary": "Pharming Group N.V. reported an 8% revenue decline in Q1 2026, leading to a 22.15% stock price drop, primarily due to competitive pressures on its RUCONEST product. Despite this, the company saw substantial growth in its Joenja franchise and reaffirmed its full-year 2026 revenue ", "url": "https://www.investing.com/news/company-news/pharming-q1-2026-slides-joenja-growth-offset-by-ruconest-decline-93CH-4668282", "source_name": "Investing.com", "published_at": "2026-07-06T06:40:19", "published_display": "06 Jul 2026 06:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "High Growth Tech Stocks In Europe Featuring 3 Promising Picks", "summary": "This article identifies three promising high-growth tech stocks in Europe: Pharming Group, Acast, and Dustin Group. It highlights their recent developments, financial performance, and growth prospects within the context of a resilient European market. The piece offers a brief ove", "url": "https://simplywall.st/stocks/nl/pharmaceuticals-biotech/ams-pharm/pharming-group-shares/news/high-growth-tech-stocks-in-europe-featuring-3-promising-pick/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T05:43:27", "published_display": "06 Jul 2026 05:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group N.V. Stock 12\u2011Month Price Target Raised to $32.69, Implies 137% Upside", "summary": "Analysts have raised the 12-monthprice target for Pharming Group N.V. (PHARM) stock to $32.69 from $31.09, based on estimates from 5 analysts. This new target implies a potential upside of approximately 137% from the July 2nd closing price. The consensus rating for the stock rema", "url": "https://www.tradingview.com/news/tradingview:cbc0a191bcaab:0-pharming-group-n-v-stock-12-month-price-target-raised-to-32-69-implies-137-upside/", "source_name": "TradingView", "published_at": "2026-07-04T22:10:14", "published_display": "04 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV - Depositary receipt (PHAR) price target increased by 43.79% to 25.84", "summary": "This article reports that the price target for Pharming Group NV (PHAR) depositary receipts has been increased by 43.79% to 25.84. No further details are provided in the snippet.", "url": "https://www.msn.com/en-us/money/topstocks/pharming-group-nv-depositary-receipt-phar-price-target-increased-by-43-79-to-25-84/ar-AA20ZBmJ", "source_name": "MSN", "published_at": "2026-07-04T18:43:27", "published_display": "04 Jul 2026 18:43", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pharming Group NV \u2013 EURONEXT:PHARM", "summary": "The article provides financial data on Pharming Group NV (EURONEXT:PHARM), specifically highlighting its enterprise value to EBIT forward. It appears to be a financial data snippet from TradingView, offering an overview of the company's financial metrics. The content is concise a", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:40:49", "published_display": "01 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pharming Group NV \u2013 EURONEXT:PHARM", "summary": "This article provides a brief overview of Pharming Group NV (EURONEXT:PHARM) on TradingView, focusing on its financial metrics, specifically the price to sales forward. It does not offer any specific financial figures or analysis but highlights the company's presence on the platf", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:39:22", "published_display": "01 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (PHAR) That Institutions Follow", "summary": "This article analyzes Pharming Group N.v. (NASDAQ: PHAR) based on AI-generated technical signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup targeting a 21.2% gain, and outlines three distinct trading strategies (Position, Momentum Breako", "url": "https://news.stocktradersdaily.com/news_release/101/The_Technical_Signals_Behind_PHAR_That_Institutions_Follow_063026070602_1782860762.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T19:06:00", "published_display": "30 Jun 2026 19:06", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V. (PHAR) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pharming Group N.V. (NASDAQ: PHAR) securities. This investigation follows a significant stock price drop after the FDA issued a Complete Response Letter to Pharming's sNDA for Joenja\u00ae,", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-pharming-group-nv-phar", "source_name": "The National Law Review", "published_at": "2026-06-30T12:39:22", "published_display": "30 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2QLQY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and forecast for Pharming Group NV Sponsored ADR (A2QLQY) for 2027, based on analysis from 6 analysts. It states a price target of 26.85 and includes sections for annual and quarterly EPS and revenue metrics. The content also contains a discla", "url": "https://www.tradingview.com/symbols/LS-A2QLQY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T11:41:52", "published_display": "29 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR)", "summary": "This article provides access to the financial actuals and estimates for Pharming Group N.V. (NASDAQ: PHAR) on TradingView. It allows users to explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends over time ac", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:36", "published_display": "27 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the 1-year price target forecast for Pharming Group NV Sponsored ADR (PHG) based on input from 6 analysts. It states a price target of 26.85 but notes that maximum and minimum estimates were not provided. The article also touches on analyst ratings, EPS, and", "url": "https://www.tradingview.com/symbols/MUN-PHG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:36", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case", "summary": "Pharming Group's fair value estimate has been raised from \u20ac2.11 to \u20ac2.36 by analysts, driven by adjusted revenue growth assumptions and revised future P/E multiples. This update reflects a balance of optimism regarding the company's growth potential, particularly with its Joenja ", "url": "https://finance.yahoo.com/markets/stocks/articles/pharming-group-enxtam-pharm-stock-130805614.html", "source_name": "Market source", "published_at": "2026-06-27T09:08:00", "published_display": "27 Jun 2026 09:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV Actuals & Estimates (EURONEXT:PHARM)", "summary": "This article provides an overview of Pharming Group NV (EURONEXT:PHARM) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers various metrics such as market capitalization, volatility, earnings, revenue, and EBITDA, while als", "url": "https://www.tradingview.com/symbols/EURONEXT-PHARM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:52", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV Actuals & Estimates (AQUISUK:PHARMA)", "summary": "This article provides details on Pharming Group NV (PHARMA) stock, including financial actuals and estimates. It covers analyst price targets with a range of 1.80 EUR to 3.45 EUR, historical price data, upcoming earnings dates, and past financial performance such as revenue, net ", "url": "https://www.tradingview.com/symbols/AQUISUK-PHARMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:31", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV (PHAR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pharming Group NV (PHAR), focusing on indicators and moving averages to assess its stock performance. It details various technical indicators like MACD, RSI, and STOCH, along with an analysis of moving averages (MA5 to MA200), conclud", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phar/technical", "source_name": "TradingKey", "published_at": "2026-06-23T01:40:06", "published_display": "23 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Pharming Group N.v. (PHAR) Risk Zones", "summary": "The article provides a detailed analysis of Pharming Group N.v. (PHAR) stock, highlighting positive near-term sentiment within a long-term strength context despite elevated downside risk due to a lack of additional long-term support signals. It outlines three AI-generated institu", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Pharming_Group_N.v._PHAR_Risk_Zones_061926055401_1781906041.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T01:10:13", "published_display": "20 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group NV (PHAR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Pharming Group NV (PHAR), indicating a \"Strong Buy\" analyst rating based on 6 analysts. It highlights that relevant financial forecasting data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. The article al", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phar/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:54", "published_display": "18 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group Says Marketing Application for Immunodeficiency Disorder Drug Accepted by FDA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pharming-group-says-marketing-application-073748059.html", "source_name": "MT Newswires", "published_at": "2026-06-04T07:37:48+00:00", "published_display": "04 Jun 2026 07:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja\u00ae (leniolisib) to treat children aged 4 to 11 years with APDS", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pharming-announces-u-fda-acceptance-050000350.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T05:00:00+00:00", "published_display": "04 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxQRHV2SjcyUngyaHBTRl95M1BYSU80c0J2X09vbEhISWMyNFlvbk9NVV84RkpuNDRiZ1lkRmdJalRqRUJEc1Y2QnFZakZlTGg0dXZzclJ4aE9JOUpEWDJVTWI4WU54X25KWmpGc3dTYkVfc2pFdEY4QXF0Q05QWDBOU2dWSGFSSFpRUHhYTklXWS1TaHFvM1FDQndpanN3aC1QMVUzaG1CVEkzUDFKd0J5d3BLR2UzZWFQczBEMElHdEpXNmZFWlExOV83TWtnMmNQUkRVOEVDbkpMNW1wbjYxMUo3U0Vsb0E4b1BQVEVWeW9wM2otZElRUlkycmcyVjY1YnV5d3hIVkw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group announces results of 2026 Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQc21sTkFCWVFoLXBNbUlDZHVncG9ydFdjNlBpU1RJY0ZJbWowRjQ4M3pwZVljMDg0bUpsejlleFd6VU05ZnpOQnZYeWlrbzFlVFFxcEkxYzJCV0ZldjIxeFlibnl4Y2tjaU5oODlJaG1lLTl6VElnc2s2amVHUWNLVlBtRTIxZXJGRnY2WWZLRmlqOEFCOEZuNm13WUd5ak5lSHk3aEs4cE11QlpEWGpIZnRrUDJObDhrZFVWajgxUVN2elJ2NWdscjJfVlpXNnhFNGhjanRRRHFDXzRrenFXaG0yV0tydw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Says European Commission Grants Marketing Authorization to Joenja", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pharming-says-european-commission-grants-195934063.html", "source_name": "MT Newswires", "published_at": "2026-05-22T19:59:34+00:00", "published_display": "22 May 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Commission grants marketing authorization to Pharming\u2019s Joenja\u00ae (leniolisib) \u2013 the first approved treatment for APDS in the European Union", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/european-commission-grants-marketing-authorization-193000990.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T19:30:00+00:00", "published_display": "22 May 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group reports first quarter 2026 financial", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxQdk9XUmNoRjVtLXJkR3VWZ0RxMkluaHQxd0JWaXNva2NuOVRIdkxXUGsxdnRlN0VqUXFqRW9NQ2NYVy1GLVZvSGFoTkUwaXlzaXM4R05WUTFpbHlSNjBVQWwzZXVhOXNLQ2lvWm5ZM3MxclBRNm0wWDFlbVlSa3d1RGVKdnhmbFNrOEdOd3B0STgwVUFUNDVKSEg2RlFVMHl2dU9BeHZnaTZUaU83YktyMGwxNkFreGdsbmxpSUFPWlBFdXpuZHNpSHhMOGotOUQzcDBKTzZVa1Nvd21ieEw3OTFxLUE1RjRJc01pYXNFd1B2bTRfTUZRNlpoWGdfdFd0a21WWlJ3Ukk1cEdKSlNyX2U1OHo5R1lpcjJaVFJtTzFidkVtTGFIbzJNdk94WW1zVjY0cy11aVJLWlNuTEg4X0pta1A?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group N.V. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PHAR) 2026-05-07", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOY1gwbEJtUkF1QVZ4RXJRUlpGaS1DdVNzcUthdlNpdVZNZlN0dkk5WGtoRjFNUC1rYmFGUEJuZFVZaXplOHY0SzRNc3lQQWtYWm4wblBMNHJyQzZUdUtHa3p5b1A1b29oWGt4T3doYmlCTE9SZE4xVUdZNzNsWUVQcmRHWFRVaC1RWU1qQjZSLXRRRFR3Ym0tNzgwVU1tUGZVaXVnRw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group: Crossing From Speculation To Profitability (NASDAQ:PHAR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOb1U3ODFlTU5Mb1Raa2xKZFFnM1huZXhKdUpwYjdKMnpkSTYzZWhEWEk3c1IwTVVHQlQ0THNsZl9JUVFSaFBzcGN6cFVLaF8wYVMwdUZ2SVJrNXFXSUVPRWJWZnZHRDkyYkNKeVBia29HcElSN1YxdTNqSlhHY2hlTjl5VjFINFRTV291LXAtNzFuQ0x1RVpGRkdaN25Yb21QVXY5aDg4Yw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Open Week In The Red As Gold, Silver Extend Sharp Selloff: Why ORCL, PLTR, DIS, PHAR, ELPW Are On Traders' Radar Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNeU00SlZPU3FCOENMUTZwMGJnYkFjTy1jNndGTzFPQ2VmN0JkTUlXcVp1YkVuRHRaNllWQkJDU09LaEpSX0NpV0tFMm1xeXNRTUdVTTJ3RXlRUl9xMDE0V1ZkLWlpNzVOWnZvcGktbjBkeE1qbFVhRE5NUVF1alRtMEZBQWNnbnFEaUFWZXdwOW5HMnJWODJTOUh5bGk0bWFpeUZwNjFhdTVyMTdwU01rVzdhdUg5ME5UalM0RnBsMm8xcGZv?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharming Group stock tumbles after FDA issues Complete Response Letter By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOWEhQQjFSTnpiZ0RsUGJQUEtzM3ExUjBjazgwVmhaUWNXV0VyRzBsQW54LWp3a3kySEdYUVJiRE5ibjdqRFhlLUlELWpRWk02R0VBWHdPOVN6eFQtRm5EeWdITTNJYUpJRzNySEcyMVFDYVNPUjRJU1pXa0N2TlJNQUxXT3czWmlteGxmNUJBVy1GUXZyZEFXOUVyeVFWOG01OU9vNXlkV2NjWU04N24wSjIwdFdsN3hDWlBQYk5qN0M2a1o5SFNoYkJWSQ?oc=5", "source_name": "Investing.com UK", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 47, "sentiment_summary": {"positive": 10, "negative": 3, "neutral": 34, "score": 54, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 10.8, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 10.66, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 10, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 13.86, "latest_week": "2026-07-10", "one_week_move": 0.7, "four_week_move": 8.2, "twelve_week_move": -20.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.164841, "market_dynamics_buy_signal": false, "relative_strength": -21.602724, "fair_value_gap": 18.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.4977, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.7% over one week, +8.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 19}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.7% over one week, +8.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Pharming Group to report Q2 and H1 2026 results on July 30"}], "updated_at": "2026-07-17T13:33:42.402291+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}